超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國BioMimetic
美國仿生治療公司（BioMimetic Therapeutics Inc.)促進肌肉骨骼損傷和疾病，包括整形外科，脊柱及運動損傷的應用愈合。仿生開發的所有產品都是基于重組人血小板衍生生長因子（rhPDGF- BB）的平臺技術，這是一種生長因子，人體的主要推動者和直接刺激愈合和再生一合成形式。

Located in Franklin, Tennessee, BioMimetic is a biotechnology company specializing in the development and commercialization of innovative drug-device combination products to promote the healing of musculoskeletal injuries and diseases, including orthopedic, spine and sports injury applications. All products developed by BioMimetic are based upon recombinant human platelet-derived growth factor (rhPDGF-BB) platform technology, which is a synthetic form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments, thus helping patients recover faster from their orthopedic injuries.

While on staff at Harvard beginning in the mid 1980s, Dr. Samuel Lynch, BioMimetic's president, CEO and founder, conducted research on the role of PDGF in tissue repair and regeneration. These efforts generated a foundation of scientific knowledge and intellectual property from which BioMimetic Therapeutics is now based.